Menu
Date: 21st-22nd of November 2024
Language: English
Key poins:
Join leading experts and innovators in high-profile discussions on genomic discovery, therapeutic targets, and cutting-edge advancements in cancer care. Explore real-world challenges and opportunities, shaping the future of precision medicine. Elevate your insights at this summit dedicated to revolutionizing oncology through collaboration and expertise.
The event would be beneficial for various professionals and stakeholders involved in the Healthcare, Genomics, Pharmaceutical Industries. Here are some key individuals and organizations who should consider joining the conference:
Welcome to the Precision Medicine In Oncology 2024 Conference — an unparalleled gathering of thought leaders, researchers, and pioneers in the field. Delve into the forefront of cancer research, exploring genomic discovery, therapeutic targets, and revolutionary advancements. Our high-profile summit provides a platform for strategic discussions, tackling real-world challenges in implementing precision medicine from bench to bedside. Engage in dynamic sessions featuring expert presentations, an interactive workshop on practical applications, and a panel discussion on navigating the dynamic landscape of precision oncology. From regulatory considerations to AI-enhanced clinical trials, this summit promises a holistic exploration of advancements in personalized therapeutics and diagnostics. Join us to be part of transformative conversations, fostering collaboration that will shape the future of precision oncology.
Barcelona stands out as an exceptional conference destination, seamlessly blending historical charm with modern amenities. Its Mediterranean location provides a picturesque backdrop, complemented by a favorable climate year-round. The city offers a variety of venues suitable for hosting conferences, from historic buildings to contemporary event spaces. Delegates can explore Barcelona’s rich cultural tapestry, immersing themselves in iconic landmarks such as the awe-inspiring Sagrada Familia and the enchanting Park Güell, both easily accessible from the conference venue. With efficient transportation links connecting it to the world, Barcelona ensures easy access for attendees. Our hotel partner offers luxurious accommodation and convenient amenities, further enhancing the conference experience.
Beyond business, the city’s dynamic atmosphere fosters networking opportunities and meaningful exchanges, making it a premier choice for conferences where professional development meets leisurely exploration.
© 2023-2024 VNA International IČO: 09236147
International Precision Medicine 2024 Conference
Hans-Peter Deigner is professor in pharmacology, deputy director of the Institute of Precision Medicine and dean of the faculty of Medical and Life Sciences at Furtwangen University. After PhD at Heidelberg University and post doc at Harvard Medical School, Boston, he finished his habilitation in pharmaceutical chemistry (Heidelberg University). He directed research in molecular diagnostics in several biotech companies, held a professorship in biomedicinal chemistry at the University of East Anglia, Norwich, UK (2004-2006) and is professor at Furtwangen University since 2011; in 2020 he became also associated member of the science faculty, Tuebingen University. So far he has published about 200 papers and acquainted many million euros for research projects. His research interest in Precision Medicine covers nanotechnology, medicinal chemistry, molecular diagnostics, smart materials and metabolomics.
For the past 27 years, Manolo E. Beelke has been deeply engaged in clinical research and drug development, with a remarkable 7-year stint in academic research within Neurology and Sleep Medicine. His journey encompasses a series of triumphs within Pharma companies, which have laid a robust foundation for spearheading ventures in start-ups and exploratory stage firms.
Throughout his career, Manolo has been handpicked for several senior executive roles, entrusted with orchestrating diverse interdisciplinary teams to yield a string of triumphant New Drug Applications (NDAs), Biologics License Applications (BLAs), and pioneering drug development initiatives. His finesse lies in assembling accomplished, high-potential talent and skillfully guiding these teams to surpass both individual and corporate aspirations.
As an independent consultant, he exudes leadership and accountability in shaping clinical development strategies, overseeing medical monitoring, offering sagacious guidance to investors, crafting regulatory strategies, medical documentation, pharmacovigilance, worldwide label scrutiny, health economics, serving as a steering committee member, and assuming the role of chairman.
In the realm of business development for pharmaceuticals and biotechnology, Manolo serves as a medical compass, identifying new prospects for acquisition among companies and compounds. At the Clinical Research Organization (CRO) level, he adeptly facilitates contact with potential new clients, leveraging his medical expertise.
His guidance has been instrumental in navigating the intricate landscape of restructuring, development, and global repositioning of a mid-sized CRO post multiple mergers and acquisitions, with the establishment of numerous dedicated units and divisions.
Manolo’s impressive contributions extend to academia as well, with over 40 peer-reviewed articles to his name. He has also shouldered the responsibility of peer-reviewing various publications, conceptualized more than 60 clinical trials, provided medical counsel across 100+ clinical trials, scrutinized over 500 study proposals, and not only chaired but also been a keynote speaker at an array of conferences, spanning the domains of Sleep Medicine, Multiple Sclerosis, and comprehensive life-cycle management.
Educationally, Manolo E. Beelke boasts an MD from the University of Genoa, Italy, and a PhD in Sleep Medicine from the University of Bologna, Italy. His training includes board certification as a Clinical Neurophysiologist from the University of Genoa, Italy, coupled with an esteemed board certification as an expert in Sleep Medicine, awarded by the Italian Society for Sleep Medicine (AIMS).
Ronan Rocle studied Chemistry at Ecole Normale Supérieure, Paris, and graduated from the MBA of Collège des Ingénieurs, Paris, in 2011. He worked in the Petrochemical branch of TotalEnergies and in a deep tech company developing biobased chemicals and fuels using Synthetic Biology, Global Bioenergies.
He joined Seqens in 2019 and is in charge of Technology Marketing.
Dr Elad Katz graduated in Chemistry and Physics from the Hebrew University of Jerusalem and worked over three years as analytical chemist in the Israeli Army Technology Unit. Elad then received a scholarship for a PhD studentship in Immunology at the University of Glasgow. His post-doctoral work span oncology and virology and he has been interested in 3D cell culture since 2001. Dr Katz is senior author on over dozen papers on oncology models from University of Edinburgh. He has worked for two SMEs as lead on complex biology models and been instrumental in spinning-out Starthclyde University technology as Screenin3D Ltd. Elad has joined the University of Dundee in 2015, initially as lead biologist in the dermatology portfolio of the Drug Discovery Unit, where he was involved in activities leading to another successful spin-out, now called Tay Therapeutics. Dr Katz has conceptualised the NaviPlate in 2018 and has secured money in the following years to produce prototypes and start developing disease models based on it, culminating in Navigate Precision Biology.
